SCHEMBL2632333

SCHEMBL2632333

COC(=O)c1ccc2nc(-c3ccccc3OC)cn2c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
ALDH1A3 P47895 2/20 0.58
RAB9A P51151 5/20 0.58
NPC1 O15118 4/20 0.58
MAPT P10636 2/20 0.58
KDM4E B2RXH2 4/20 0.56
GLA P06280 1/20 0.56
KMT2A Q03164 1/20 0.52
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
ALDH1A2 O94788 1/20 0.46
ADORA3 P0DMS8 4/20 0.45
TLR9 Q9NR96 1/20 0.45
HPGDS O60760 2/20 0.43
PIK3CD O00329 1/20 0.43
PIK3CG P48736 1/20 0.43
ADORA1 P30542 2/20 0.43
SIRT5 Q9NXA8 1/20 0.43
VDR P11473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8477131 0.85 RAB9A (0.64) ALDH1A1ALDH1A3RAB9ANPC1MAPT
SCHEMBL2128966 0.85 ALDH1A1 (0.58) ALDH1A1ALDH1A3RAB9ANPC1MAPT
SCHEMBL2127835 0.85 ALDH1A1 (0.58) ALDH1A1ALDH1A3RAB9ANPC1MAPT
SCHEMBL2127588 0.82 ALDH1A1 (0.55) ALDH1A1ALDH1A3RAB9ANPC1MAPT
SCHEMBL407421 0.82 ALDH1A1 (0.83) ALDH1A1ALDH1A3RAB9ANPC1MAPT
SCHEMBL2129269 0.81 RAB9A (0.56) ALDH1A1ALDH1A3RAB9ANPC1MAPT
SCHEMBL2127115 0.80 ALDH1A1 (0.88) ALDH1A1ALDH1A3RAB9ANPC1MAPT
SCHEMBL2127939 0.78 NPC1 (0.58) ALDH1A1ALDH1A3RAB9ANPC1MAPT
SCHEMBL2128899 0.77 ALDH1A1 (0.72) ALDH1A1ALDH1A3RAB9ANPC1MAPT
SCHEMBL2127209 0.77 NPC1 (0.76) ALDH1A1ALDH1A3RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US disclosed
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US disclosed
EP-2129375-B1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2012-04-25 EP disclosed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
WO-2008104278-A1 IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-09-04 WO disclosed
EP-1964840-A1 Imidazo[1,2-a]pyridines and their use as pharmaceuticals sanofi-aventis (FR) 2008-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS NOS1, PTGIS, NOS2 ALDH1A1 1286/4885ALDH1A3 2825/4885RAB9A 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.